Mammary glands reconstituted with Neu/ErbB2 transformed HC11 cells provide a novel orthotopic tumor model for testing anti-cancer agents.
about
Erk regulation of pyruvate dehydrogenase flux through PDK4 modulates cell proliferationBAD: a good therapeutic target?HER4 D-box sequences regulate mitotic progression and degradation of the nuclear HER4 cleavage product s80HER4.ErbB2 enhances mammary tumorigenesis, oncogene-independent recurrence and metastasis in a model of IGF-IR-mediated mammary tumorigenesis.Wnt1 and Wnt5a induce cyclin D1 expression through ErbB1 transactivation in HC11 mammary epithelial cells.Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy.The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesisTargeting the function of the HER2 oncogene in human cancer therapeutics.Tyrosine kinases as targets in cancer therapy - successes and failures.Molecular Mechanisms of Trastuzumab-Based Treatment in HER2-Overexpressing Breast CancerHigh-resolution in vivo imaging of fluorescent proteins using window chamber models.HER-2-directed, small-molecule antagonistsKRas induces a Src/PEAK1/ErbB2 kinase amplification loop that drives metastatic growth and therapy resistance in pancreatic cancer.cDNA microarray analysis of invasive and tumorigenic phenotypes in a breast cancer model.ErbB1 and prostate cancer: ErbB1 activity is essential for androgen-induced proliferation and protection from the apoptotic effects of LY294002.Anticancer Properties of Halogenated Pyrrolo[3,2-d]pyrimidines with Decreased Toxicity via N5 Substitution.IL-15 augments antitumoral activity of an ErbB2/HER2 cancer vaccine targeted to professional antigen-presenting cells.
P2860
Q24323390-3A4515D7-9E3D-4A57-85A5-9EF922C69C5FQ24795051-A49CB77E-C2C7-4932-8FB3-2F94C46D3FBFQ34048293-D49C068E-F932-4A72-8843-665F502D7453Q34133760-887E7373-73F1-4B8A-9857-417746D1E535Q34227971-CE1A1744-5750-4177-B8BA-527128358A56Q34394487-4DDCCC64-0EEF-446A-A525-9506F5D78E72Q34493341-A7B076CA-EAC9-4B75-B110-69594905D950Q34766486-5289D5EB-1E35-4EF9-A06C-A1A1EF135435Q35095147-63CB51AA-00C6-4C50-BCF8-7615A99D6328Q36440214-58DED7ED-7342-48AC-A351-31F8E3BE8410Q37078073-B3563DCC-37EF-4638-A814-D189BD8504DBQ37336019-2CE1DACC-E1A6-40D7-92EF-5E2FEE8F57A0Q39347740-2867BF44-32CA-42BA-8AB0-0D3DE63686B3Q40591603-06644932-7B56-4D60-8CAD-025FD37574BEQ40647881-41565606-B248-4BD7-8784-44B1D124FE74Q47385841-4CC73C9F-DEBB-4863-812A-64558D629EB8Q54530047-483CFB37-C37F-4293-89CE-B0EB862B463C
P2860
Mammary glands reconstituted with Neu/ErbB2 transformed HC11 cells provide a novel orthotopic tumor model for testing anti-cancer agents.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Mammary glands reconstituted w ...... or testing anti-cancer agents.
@en
type
label
Mammary glands reconstituted w ...... or testing anti-cancer agents.
@en
prefLabel
Mammary glands reconstituted w ...... or testing anti-cancer agents.
@en
P2093
P2860
P356
P1433
P1476
Mammary glands reconstituted w ...... or testing anti-cancer agents.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.ONC.1204709
P407
P577
2001-09-01T00:00:00Z
P5875
P6179
1020279103